Diagnosis & Differentiation
GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis
Virchows Archiv 2021 February 11 [Link] Zheng Hua Piao, Xin Cheng Zhou, Jia Yi Chen Abstract Sarcomatoid malignant mesothelioma (SMM) tends to occur in the pleura and is morphologically similar to lung sarcomatoid carcinoma (LSC) and organizing pleuritis (OP). Because SMM often does not express mesothelial markers, it is very difficult to distinguish from LSC…
Read MoreSerum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial
Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…
Read MorePotential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma
Oncology Letters 2021 February [Link] Vincenzo Fontana, Maria Pia Pistillo, Antonella Vigani, Pier Aldo Canessa, Giovanni Berisso, Ugo Giannoni, Paola Ferro, Maria Cristiana Franceschini, Roberta Carosio, Marika Tonarelli, Paolo Dessanti, Silvio Roncella Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor survival rates. Therefore, it is essential to have effective biological markers predicting…
Read MoreAlterations in BAP1 are Associated with Cisplatin Resistance Through Inhibition of Apoptosis in Malignant Pleural Mesothelioma (MPM)
Clinical Cancer Research 2021 February 5 [Link] Kathrin Oehl, Bart Vrugt, Ulrich Wagner, Michaela B Kirschner, Mayura Meerang, Walter Weder, Emanuela Felley-Bosco, Bernd Wollscheid, Katrin Bankov, Melanie C Demes, Isabelle Opitz, Peter J Wild Abstract Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of…
Read MoreMalignant pleural mesothelioma in a patient with pneumothorax: A cumbersome subtype both clinically and pathologically
Thoracic Cancer 2021 February 2 [Link] Takafumi Fukui, Takako Okubo, Naoki Tanimoto, Hiromichi Okuma, Yoshitaka Shiina, Mizuki Kohama, Jun Yamada, Yasuhiro Funada, Yoshihiro Ikura Abstract Here, we report a case of malignant pleural mesothelioma (MPM) that was very difficult to diagnose. A 62-year-old woman with a surgical history of recurrent bilateral pneumothorax was admitted to…
Read MoreRucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
The Lancet Respiratory Medicine 2021 January 27 [Link] Dean A Fennell, Amy King, Seid Mohammed, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Adrian Nicholson, Cathy Richards, Peter Wells-Jordan, Gavin James Murphy, Anne Thomas Abstract Background: Malignant mesothelioma remains an incurable cancer, with no effective treatments in the…
Read MoreUnusual radiologic presentations of malignant peritoneal mesothelioma
World Journal of Radiology 2020 December 28 [Link] Paul Hendrick Sugarbaker, James S Jelinek Abstract Background: Malignant peritoneal mesothelioma is an unusual disease process characterized radiologically by ascites and infiltration of the peritoneum by multiple small tumor nodules. Both parietal and visceral peritoneum are involved by the multiple malignant tumor nodules. Computed tomography (CT) has…
Read MoreClinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting
Acta Oncologica 2021 January 27 [Link] Thomas Ringgaard Petersen, Vasiliki Panou, Christos Meristoudis, Ulla Møller Weinreich, Oluf Dimitri Røe Abstract Background: This study aims to investigate patient- and disease characteristics associated with survival in malignant pleural mesothelioma (MPM) patients with anti-tumor treatment or with best supportive care (BSC). Materials and methods: Consecutive MPM cases diagnosed…
Read MoreHigher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma
Cancer Cytopathology 2021 January 25 [Link] Mohammed S I Mansour, Tomas Seidal, Ulrich Mager, Katalin Dobra, Hans Brunnström, Annika Dejmek Abstract Background: Malignant mesothelioma (MM) is a therapy-resistant tumor, often causing an effusion. Drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have shown promising results, but assessment of PD-L1…
Read MoreFluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma
Cancer Cytopathology 2021 January 25 [Link] Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Masayo Yoshimura, Ayuko Sato, Tohru Tsujimura, Toshiaki Kamei, Kunimitsu Kawahara, Akinori Iwasaki, Kazuki Nabeshima Abstract Background: Malignant pleural mesothelioma (MPM) is characterized by mutations in several genes, including cyclin-dependent kinase-inhibitor 2A/p16 in the 9p21 locus, BRCA1-associated protein 1 (BAP1), and neurofibromatosis type 2…
Read More